title: Antinociception induced by microinjection of substance P into the A7 catecholamine cell group in the rat.
abstract: Stimulation of neurons in the ventromedial medulla produces antinociception that is mediated in part by indirect activation of pontospinal noradrenergic neurons. Substance P-containing neurons located in the ventromedial medulla project to the A7 catecholamine cell group and may serve as an excitatory link between these two cell groups. Thus, the antinociception induced by stimulation of the neurons in ventromedial medulla may be mediated by substance P released from these projections which activates spinally projecting noradrenergic neurons in the A7 cell group. This hypothesis was tested by determining whether microinjection of various doses of substance P into the A7 cell group of the rat could induce antinociception. The results indicated that substance P induced dose-dependent antinociception that was more pronounced in the hindlimb ipsilateral to the microinjections. This observation is consistent with anatomical observations that noradrenergic A7 neurons project predominantly to the ipsilateral spinal cord dorsal horn. Moreover, the antinociceptive effects of substance P microinjection appear to be mediated at least in part by activation of spinally projecting noradrenergic neurons in the A7 cell group, because intrathecal injections of the alpha-2 noradrenergic antagonists yohimbine and idazoxan blocked these antinociceptive effects. The results of these experiments support the hypothesis that the antinociception induced by stimulation of neurons in the ventromedial medulla is mediated in part by activation of substance P-containing neurons that project to, and activate, spinally projecting noradrenergic neurons located in the A7 catecholamine cell group.
authors.affiliation: Department of Pharmacology, University of Illinois, Chicago 60680.
authors.forename: D C
authors.initials: DC
authors.lastname: Yeomans
authors.forename: H K
authors.initials: HK
authors.lastname: Proudfit
mesh_terms: D000344:Afferent Pathways / Q000502:physiology; D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D002395:Catecholamines / Q000502:physiology*; D004146:Dioxanes / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006358:Hot Temperature; D019329:Idazoxan; D007278:Injections, Spinal; D008845:Microinjections; D008959:Models, Neurological; D009474:Neurons / Q000502:physiology; D009638:Norepinephrine / Q000502:physiology; D010146:Pain / Q000503:physiopathology*; D011149:Pons / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D051381:Rats; D011919:Rats, Inbred Strains; D012018:Reflex; D012701:Serotonin / Q000502:physiology; D012881:Skin Temperature / Q000187:drug effects*; D013238:Stereotaxic Techniques; D013373:Substance P / Q000008:administration & dosage / Q000494:pharmacology*; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis; D015016:Yohimbine / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000700:Analgesics; D002395:Catecholamines; D004146:Dioxanes; D015016:Yohimbine; D012701:Serotonin; D013373:Substance P; D014446:Tyrosine 3-Monooxygenase; D009638:Norepinephrine; D019329:Idazoxan